In 2017, FDA approved Venetoclax, a novel BCL-2 inhibitor targeting the PPIs between BCL-2 and other proteins in acute myeloid leukemia treatment (DiNardo et al., 2019; Guerra et al., 2019). This evidence concerns the gene BCL2 and acute myeloid leukemia.